T he discovery that inhibition of vascular endothelial growth factor (VEGF) suppressed neovascularization 1 revolutionized the management of neovascular retinopathies, such as age-related macular degeneration and diabetic retinopathy. 2, 3 Anti-VEGF agents are now used to treat the end stages of these diseases when neovascularization and vascular leakage has developed and vision is threatened. 2, 3 However, the prevention of retinal vasculopathy remains an unmet and urgent need because disease prevalence continues to be an escalating global health burden. [2] [3] [4] A compounding factor is that a substantial number of eyes insufficiently respond to anti-VEGF agents. 5 The retinoic acid receptor-related orphan nuclear receptors (ROR) are transcriptional regulators comprised of RORα, RORβ, and RORγ. 6, 7 RORs have important roles in various biological processes, including lipid and steroid metabolism, oxidative stress, and tissue pathologies. 6 In terms of vasculopathy, a recent study demonstrated that RORα influences neovascularization, 8 but little is known about the contribution of other ROR isoforms. We proposed that RORγ has unrecognized proangiogenic properties in the retina because of its central role in interleukin (IL)-17 production. 6, 9 IL-17 refers to a family of 6 cytokines (IL-17A to F), with IL-17A (often denoted as IL-17) the most investigated and well characterized. 9 There is an increasing evidence that IL-17 has proangiogenic effects in autoimmune diseases and tumors via the upregulation of VEGF. 10 Of potential relevance to the treatment of neovascular retinopathies is that tumors are resistant to the antiangiogenic effects of VEGF blockade because of the presence of IL-17. 11 Yet, there is limited information about the role of RORγ and IL-17 in neovascular retinopathies, albeit the elevated levels of IL-17 in the plasma of patients with diabetic retinopathy 12 and retinopathy of prematurity 13 is highly suggestive of a causal role for these factors in disease pathogenesis.
RORγ has a predominant role in the differentiation of T helper 17 (Th17) cells 7, 14 and production of IL-17 from this
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Dean M. Talia, Devy Deliyanti, Alex Agrotis, Jennifer L. Wilkinson-Berka cell type and other immune cell populations, including natural killer T cells, γδT cells, lymphoid tissue inducer cells, neutrophils, and macrophages. 9, 15 Microglia are the resident immunocompetent cells of the retina, and when chronically activated in disease, release proinflammatory signals that stimulate the production of trophic factors from neuroglial cells. 16, 17 Hence, it is not surprising that activated microglia have a central role in the pathogenesis of neovascular retinopathies. 17 However, it is unknown if retinal microglia produce IL-17 via RORγ, and if IL-17 stimulates the release of VEGF from the key neuroglial cell populations involved in retinal vasculopathy, namely macroglial Müller cells and neuronal ganglion cells. 18, 19 We hypothesized that RORγ and IL-17A promote vascular pathology in the ischemic retina by processes involving neuroglial cells and VEGF. We utilized primary cultures of retinal microglia, macroglial Müller cells, and neurons to determine the cellular source of IL-17A and if RORγ influences its production. Furthermore, we investigated a robust model of retinopathy of prematurity, oxygen-induced retinopathy (OIR), to examine the efficacy of RORγ inhibition and IL-17A neutralization on retinal vasculopathy, the expression of angiogenic factors, gliosis, and ganglion cell loss.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Retinal Microglia, But Not Müller Cells and Ganglion Cells Produce IL-17A Via RORγ
To investigate the source of IL-17A, we performed immunolabeling on retina. Because IL-17A seemed to be present in microglia of OIR mice, we performed dual immunolabeling with IL-17A and the microglial marker, ionized calciumbinding adaptor protein-1 (Iba1). Confocal microscopy revealed that IL-17A immunolabeling was not present in room air controls, but in OIR mice was present in Iba1-positive microglia associated with blood vessels at the retinal surface ( Figure 1A ). The positive control for IL-17A immunolabeling was mouse spleen ( Figure I in the onlineonly Data Supplement). We confirmed that retinal microglia express IL-17 in OIR using flow cytometry to measure the abundance of CD45+CD11b+IL-17A+ cells ( Figure 1B) . We next investigated if the ROR isoforms were expressed in retina. In retina of C57BL/6J mice and Sprague Dawley rats, mRNA for RORγ, the predominant ROR isoform involved in IL-17 production, 7 as well as RORα and RORβ were present ( Figure 1C) . RORγt, the ROR isoform associated with Th17 cells, 7 was not detected, but expressed in mouse and rat thymus, which served as a positive control ( Figure 1C ). We next studied primary cultures to determine if microglia expressed ROR isoforms, as well as macroglial Müller cells and ganglion cells, as they are key contributors to VEGF production. 18, 19 In all cell types, RORα, RORβ, and RORγ, but not RORγt were detected ( Figure 1D ). Because the presence of RORγ mRNA does not necessarily result in IL-17A production in disease, 14 we evaluated the effects of hypoxia, the in vitro counterpart of the retinal ischemia that occurs in OIR. In hypoxia, retinal microglia expressed IL-17A protein in cell lysates, which was reduced by the RORγ inhibitor, digoxin 20 ( Figure 1E ). However, IL-17A was not expressed in Müller cells and ganglion cells exposed to hypoxia, or in the presence of IL-1β, which influences IL-17A production 21 ( Figure  1F-1G ). As our results indicated that microglia were the main retinal cell type producing IL-17A, we further evaluated if this was linked to RORγ. In cultured microglia, hypoxia increased the protein levels of IL-17A in cell supernatant, IL-17A and RORγ mRNA and the mRNA levels of tumor necrosis factor (TNFα), a cytokine that potentiates IL-17-mediated events 22 ( Figure 1H-1K ). Digoxin (1 μmol) and the RORα/RORγ inverse agonist, SR1001, 23 reduced all tested factors, including RORγ mRNA (10 μmol and also 5 μmol for IL-17A and TNFα mRNA; Figure 1H Figure 2C ), one of the key intracellular signaling pathways involved in the actions of IL-17A, 24 and stimulated the secretion of VEGF and TNFα ( Figure 2D-2E ). Ganglion cells also responded to IL-17A by secreting VEGF into cell supernatant ( Figure 2F ).
RORγ Inhibition Reduced Vasculopathy and Angiogenic Factors in OIR
Digoxin and SR1001's reduction of IL-17A in vitro suggested that RORγ inhibition might protect against vasculopathy in OIR. The retinal vasculature seemed normal in room air controls ( Figure 3A ). By contrast, in OIR mice administered vehicle, vasculopathy developed in the expected manner 25 with vaso-obliteration in the central retina and neovascularization in the midperipheral retina ( Figure 3A ). In OIR, digoxin and SR1001 reduced retinal vaso-obliteration and neovascularization ( Figure Retinal microglia produce interleukin (IL)-17A via retinoic acid receptor-related orphan nuclear receptor γ (RORγ). A, Representative confocal microscopy images of retina from C57BL/6J mice. In oxygen-induced retinopathy (OIR), dual immunolabeling for IL-17A (green, arrows) and the microglial marker, ionized calcium-binding adaptor protein-1 (Iba1; red, arrows), revealed IL-17A in microglia (arrowheads) associated with blood vessels at the retinal surface (asterisk). IL-17A immunolabeling was not detected in room air controls. Merged images with DAPI nuclear stain (4′,6-diamidino-2-phenylindole; blue); 5 µm cryosections. Magnification ×400. Scale bar, 60 µm. Inset is a high-powered image of IL-17A+ microglia. 3E-3I). As expected, 25 mice with OIR gained less weight than age-matched room air control mice. Digoxin and SR1001 did not influence the body weights of mice (Table I in 
RORγ Inhibition Reduced IL-17A-Positive Microglia and Müller Cell Gliosis in OIR
To determine if the protective effects of RORγ inhibition in OIR involved microglial-derived IL-17A, we performed dual immunolabeling with Iba1 and IL-17A. The OIR-induced increase in IL-17A immunolabeling in microglia was reduced with both digoxin and SR1001 ( Figure 4A ). To further evaluate the effect of RORγ inhibition on microglia, we quantitated Iba1-positive microglia. In room air controls, microglia were sparse ( Figure 4B ), but in OIR control mice administered vehicle, were increased and often associated with blood vessels ( Figure 4B ). In OIR mice, Iba1-positive microglia were reduced with both digoxin and SR1001 treatment ( Figure 4B and 4D). In OIR, the increased production of VEGF by Müller cells is accompanied by their cellular damage, which is readily demonstrated by the increased expression of glial fibrillary acid protein (GFAP). 26 To determine if RORγ inhibition influenced Müller cell gliosis in OIR, we evaluated GFAP immunolabeling. As expected, 27 GFAP immunolabeling was restricted to the retinal surface in room air controls and in OIR control mice was present in the processes of Müller cells ( Figure 4C ). Both digoxin and SR1001 reduced the OIR-mediated increase in GFAP immunolabeling ( Figure 4C and 4E) , as well as the mRNA levels of GFAP ( Figure 4F ).
IL-17A Neutralization Reduced Vasculopathy and Angiogenic Factors in OIR
To determine if the direct inhibition of IL-17A protected against retinal vasculopathy, we evaluated the effects of IL-17A neutralization. The retinal vasculature seemed normal in all room air control groups ( Figure 5A ). In OIR, IL-17A neutralization reduced retinal vaso-obliteration by 75% and neovascularization by 41% (Figure 5A-5C ). Furthermore, in OIR mice, IL-17A neutralization attenuated retinal vascular leakage ( Figure 5D ) and the increased mRNA and protein levels of VEGF and PlGF, as well as TNFα mRNA (Figure 5E-5I) . The IL-17A neutralizing antibody had no effect on the body weight of mice (Table I in 
IL-17A Neutralization Reduced Iba1-Positive Microglia and Müller Cell Gliosis in OIR
We evaluated if IL-17A neutralization protected against the increased microglial cell density and Müller cell gliosis that occurs in OIR. In OIR, IL-17A neutralization reduced 
RORγ Inhibition and IL-17A Neutralization Prevented Ganglion Cell Loss in OIR
OIR is associated with the death of retinal ganglion cells. 28 We studied the transcription factor Brn3a, a product of the pou4fl gene and a robust marker of ganglion cell nuclei, 29 to determine if RORγ inhibition and IL-17A neutralization influenced the loss of ganglion cells. In OIR, fewer Brn3a-positive ganglion cells were detected compared with room air controls ( Figure 7) . In OIR, digoxin, SR1001, and IL-17 neutralization prevented the reduction in Brna3-positive ganglion cell nuclei (Figure 7) . Retinoic acid receptor-related orphan nuclear receptor γ (RORγ) inhibition reduced vasculopathy in oxygen-induced retinopathy (OIR). A, Representative retinal wholemounts labeled with isolectin to demonstrate the vasculature. Scale bar, 0.25 mm. Room air controls have normal blood vessels. In OIR mice administered vehicle (V), vaso-obliteration (VO) and neovascularization (arrows) developed. In OIR, digoxin (DIG) and SR1001 reduced vasculopathy. B, Percentage of VO per retina in OIR. C, Percentage of neovascularization per retina in OIR. n=7 to 8 mice per group. **P<0.01 to OIR+V. D, In OIR, vascular leakage was reduced by DIG and SR1001. In OIR, mRNA and protein for VEGF (E, F), mRNA and protein for placental growth factor (PlGF; G, H), and TNFα mRNA (I) in retina were reduced by DIG and SR1001. n=5 to 9 mice per group. *P<0.05, **P<0.01, and ***P<0.001 to room air control+V. #P<0.05, ##P<0.01 to OIR+V. Mean±SEM.
Discussion
Recent research has focused on the development of treatment strategies that effectively suppress the excess VEGF and proangiogenic factors produced in neovascular retinopathies. 4, 5 The major finding of this study is that RORγ and IL-17A are previously unrecognized mediators of VEGF production in neuroglial cells of the retina in OIR. Our data indicate that microglia produce IL-17A via RORγ, and IL-17A induces the secretion of VEGF from Müller and ganglion cells. The ability of RORγ blockade and IL-17A neutralization to suppress in OIR the elevated levels of VEGF, associated angiogenic factors and IL-17A, highlights the potential therapeutic use of these treatment approaches. This is supported by these interventions conferring considerable retinoprotection in OIR, including a reduction in capillary degeneration, neovascularization, vascular leakage as well as glial cell dysfunction and ganglion cell loss.
Activated microglia are an important contributor to neovascular retinopathies because of their release of injurious growth factors, reactive oxygen species, and cytokines. Here, we provide the first report that retinal microglia express IL-17A in OIR and produce this cytokine in response to hypoxia. Typically, Th17 cells are viewed to be the major source of IL-17 because of the activity of RORγ, 7,9 although increasing evidence indicates that other immune cell populations, such as macrophages, γδT cells, lymphoid tissue inducer cells, and natural killer cells, express RORγ and produce IL-17 when exposed to various pathological stimuli. 9 We utilized a combination of confocal microscopy, flow cytometry, and primary cultures to demonstrate that retinal microglia are the predominant source of IL-17 in OIR retina. These findings do not exclude possible contributions from other immune cell types expressing IL-17, albeit these populations when present in low abundance in small tissues such as neonatal retina are difficult to detect with techniques, such as flow cytometry. We verified that microglia produce IL-17 via RORγ as digoxin, identified as a RORγ inhibitor that does not influence other ROR isoforms, 20, 31 attenuated the hypoxiainduced increase in IL-17A protein and mRNA levels. To be considered when interpreting these findings is that the actions of digoxin may not entirely be because of RORγ, as digoxin acts as a cardiac glycoside to inhibit Na + /K + ATPase activity 32 and also suppresses the activation of hypoxia-inducible factor-1α. 33 However, our findings were validated with SR1001, a first-in-class highly selective inverse agonist of RORα and RORγ that effectively suppresses Th17 cell differentiation and IL-17 production. 23, 34 Notably, in microglia, both digoxin and SR1001 reduced the hypoxia-induced upregulation of RORγ but not RORα, indicating that the production of IL-17A is linked to RORγ. In OIR, mRNA and protein for vascular endothelial growth factor (VEGF, E and F), mRNA and protein for placental growth factor (PlGF) (G, H), and tumor necrosis factor-α (TNFα) mRNA (I) in retina were reduced by IL-17A neutralization. n=5 to 9 mice per group. **P<0.01, **P<0.01, and ***P<0.001 to room air controls. #P<0.05, ##P<0.01 to OIR+IgG1 antibody. Mean±SEM.
IL-17 has a key role in host pathogen defense, whereas its overproduction promotes inflammation and damage to tissues in various autoimmune diseases. 9, 35 Additional roles for IL-17 have emerged including the stimulation of angiogenesis via the induction of VEGF 10, 36, 37 and angiogenic and inflammatory cytokines, such as TNFα. 38 IL-17-mediated events occur after its engagement with the IL-17 receptors (RA and RC), 39 and subsequent activation of intracellular signaling pathways, including extracellular-regulated kinase 1/2. 24 In retinopathy of prematurity and diabetic retinopathy, damage to macroglial Müller cells results in this cell type becoming a major producer of VEGF to result in neovascularization and vascular leakage. 18, 26 We uncovered that Müller cells express IL-17RA and IL-17RC and are key responders to IL-17A by stimulating the phosphorylation of extracellular-regulated kinase 1/2 and production of VEGF and TNFα. Ganglion cells also have the capacity to synthesize VEGF in situations of retinal disease. 19 Hence, our finding that IL-17A induces the secretion of VEGF from ganglion and Müller cells highlights the potency of IL-17A as a proangiogenic mediator in the retina. Moreover, our results suggest that microglial-derived IL-17A promotes VEGF production from retinal neuroglial cells, albeit a limitation of this study was that we did not directly establish this relationship. Previous studies indicate that cytokines such as IL-6 may work cooperatively with IL-17 to promote injury in the eye. 40 The elevated secretion of IL-6 from retinal microglia exposed to hypoxia 27 as well as increased IL-6 expression in retinal tissue in the early neovascular phase of OIR 41 suggest that IL-6 and possibly other cytokines may potentiate the actions of IL-17 in OIR.
In 2011, Huh et al 20 performed a chemical screen of 4812 compounds and identified digoxin as a specific inhibitor of RORγt transcriptional activity, findings that have been confirmed by other groups. 31 The specificity of digoxin was demonstrated by its inhibition of Th17 cell differentiation and amelioration of Th17-mediated autoimmune disease in mice. 20 A previous study reported that digoxin reduced retinal neovascularization by a mechanism related to the suppression of hypoxia-inducible factor-1α protein levels and target genes, including VEGF. 42 In this study, we confirmed digoxin's ability In room air controls, GFAP immunolabeling is confined to the retinal surface (asterisk), but in OIR+IgG1 mice, GFAP is detected throughout the retina in Müller cell processes (arrows). In OIR, IL-17A neutralization reduced GFAP immunolabeling. Iba1 (C) and GFAP (D) immunolabeling was quantitated over the entire retina and is presented as the percentage per field of retina. E, GFAP mRNA levels in retina. n=5 to 7 mice per group. **P<0.01, ***P<0.001 to room air controls. #P<0.05, ##P<0.01 to OIR+IgG1. Mean±SEM. GCL indicates ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; and ONL, outer nuclear layer.
to attenuate retinal neovascularization. However, our findings that digoxin reduced IL-17A and RORγ in microglia exposed to hypoxia and also IL-17A-immunolabeled microglia in OIR are consistent with digoxin's retinoprotective effects being due, at least in part, to antagonism of RORγ. Importantly, we extended the protective actions of digoxin in OIR to a reduction in visionthreatening capillary degeneration and vascular leakage, as well as Iba1-positive microglia, ganglion cell loss and Müller cell gliosis, which contribute to breakdown of the blood retinal barrier. 26, 43 Moreover, in OIR mice, digoxin reduced the elevated levels of powerful proangiogenic factors in the retina, including VEGF, PlGF, and TNFα. 44, 45 PlGF is part of the VEGF family, and both synergizes and forms heterodimers with VEGF to stimulate blood vessel growth. 46 Indeed, both VEGF and PlGF are targeted in antiangiogenic treatments for retinopathy, such as aflibercept, 47 and genetic deletion of PlGF in mice protects the retina against diabetic-induced vascular damage. 45 Confirmation of a central role for RORγ in OIR was achieved with SR1001, a compound that suppresses the actions of RORα and RORγ.
15 SR1001 has been reported to reduce neovascularization in OIR, which was attributed to its effects on RORα. 8 Here, we demonstrated that in OIR, SR1001 has similar effects to digoxin by reducing vasculopathy and proangiogenic factors as well as both IL-17A and RORγ expression. Together, our findings indicate that the beneficial effects of digoxin and SR1001 in OIR involve the RORγ/IL-17A pathway.
A major outcome of this study was that IL-17A neutralization attenuated retinal vasculopathy as well as microglial cell density, Müller cell gliosis, and ganglion cell loss, findings not previously reported in OIR. These results are consistent with evidence that IL-17A promoted blood vessel growth in Matrigel plugs 37 and increased vascular density in tumors and neovascularization in cornea. 48 Of particular interest was the ability of IL-17A neutralization to reduce the elevated levels of VEGF, PlGF, and TNFα in the retina of OIR mice. Currently, anti-VEGF agents such as bevacizumab and aflibercept are used to treat patients with diabetic retinopathy and age-related macular degeneration, 2,3 although seldom used for retinopathy of prematurity because of VEGF's key role in neuroprotection in the developing retina. 49, 50 IL-17A blockade may have potential as a new therapeutic avenue for retinopathy of prematurity as well as complement current anti-VEGF approaches for some neovascular retinopathies and have use for eyes resistant to anti-VEGF agents. 5 Supporting this idea is an elegant study by Chung et al 11 showing that IL-17A is responsible for mediating resistance to the antiangiogenic effects of VEGF blockade in the tumor microenvironment. Inhibition of retinoic acid receptor-related orphan nuclear receptor γ (RORγ) and interleukin (IL)-17 neutralization reduced ganglion cell loss in oxygen-induced retinopathy (OIR). Magnification ×400. Scale bar, 60 μm. Representative 3 μm paraffin sections of retina immunolabeled with Brn3a, a marker of ganglion cell nuclei. A, Brn3a-positive ganglion cell nuclei (arrows) were reduced in OIR compared with room air controls. In OIR mice treated with digoxin, SR1001, and an IL-17A neutralizing antibody, the number of Brn3a-positive ganglion cell nuclei were increased compared with OIR. B, n=5 to 7 mice per group. *P<0.05 to room air control. #P<0.05 to OIR+V. Mean±SEM. GCL indicates ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; and V, vehicle.
In conclusion, increasing evidence indicates that reducing IL-17A by RORγ inhibition has beneficial effects in various disease contexts, including diabetes mellitus and arthritis. 34, 51, 52 The ability of RORγ inhibition and IL-17A neutralization to attenuate elevated levels of angiogenic factors and vasculopathy in OIR highlights these approaches as potential new strategies for the treatment of neovascular retinal disease.
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